Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults: findings from the EPIC-Spain cohort.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Tormo, M. Jose
Chirlaque, M. Dolores
Quiros, J. Ramon
Sanchez, M. Jose
Gonzalez, Carlos A.
MetadataShow full item record
AbstractAromatic compounds such as polycyclic aromatic hydrocarbons, arylamines and heterocyclic amines require metabolic activation to form metabolites able to bind to DNA, a process mediated by polymorphic enzymes. We measured aromatic DNA adducts in white blood cells by the (32)P-post-labelling assay in a sample of 296 healthy adults (147 men and 149 women) from five regions of Spain. We also analyzed functional polymorphisms in the metabolic genes CYP1A1, CYP1A2, EPHX1, GSTM1, GSTT1, NAT2 and SULT1A1. A significant increased level of DNA aromatic adducts was found related to the fast oxidation-hydrolysis phenotype defined by the polymorphism I462V in CYP1A1, the allele A in IVS1-154C>A of CYP1A2 and the combination Tyrosine-Arginine for Y113H and H139R of EPHX1. Geometric means (adducts per 10(-9) normal nucleotides) were 2.17, 4.04 and 6.30 for slow, normal and fast phenotypes, respectively (P-trend = 0.01). Slow acetylation by NAT2 was associated with a significant decrease in adduct level; subjects with slow alleles *5A and *7A/B had in average 1.56 x 10(-9)adducts, as compared with 5.60 for those with normal NAT2 activity (P-value = 0.01). No association was seen with polymorphisms of other metabolic genes such as GSTM1, GSTT1 or SULT1A1. We concluded that the metabolic pathways of oxidation, hydrolysis and acetylation are relevant to the formation of bulky DNA adducts. This could suggest a potential involvement of aromatic compounds in the formation of such adducts; however, given lack of specificity of the post-labeling assay, a firm conclusion cannot be drawn.
CitationCarcinogenesis 2009, 30 (6):968-976
SponsorsEuropean Commission (SO 97 200302 05F02); Spanish Ministry of Health (Exp. 02-0652); Red Tema´tica de Investigacio´n Cooperativa de Centros de Ca´ncer (C03/10); Regional Governments; International Agency for Research on Cancer (AEP/93/02); Institut d’Investigacio´ Biome`dica de Bellvitge (R.I.); Environmental Cancer Risk, Nutrition and Individual Susceptibility, a Network of Excellence of the 6th EU Framework Program (FP6, FOOD-CT-2005-513 943 to A.A., C.A.G., N.S., G.C.).
- GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population.
- Authors: Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, Scotto di Carlo A, Porru S
- Issue date: 2004 Jul 1
- Influence of GSTM1 and NAT2 genotypes on placental DNA adducts in an environmentally exposed population.
- Authors: Topinka J, Binková B, Mracková G, Stávková Z, Peterka V, Benes I, Dejmek J, Lenícek J, Pilcík T, Srám RJ
- Issue date: 1997
- Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.
- Authors: Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary ES, Hassan MM, Li D
- Issue date: 2002 Feb
- Influence of genetic polymorphisms on biomarkers of exposure and effects in children living in Upper Silesia.
- Authors: Mielzynska-Svach D, Blaszczyk E, Butkiewicz D, Durzynska J, Rydzanicz M
- Issue date: 2013 Sep
- Modulation of DNA and protein adducts in smokers by genetic polymorphisms in GSTM1,GSTT1, NAT1 and NAT2.
- Authors: Godschalk RW, Dallinga JW, Wikman H, Risch A, Kleinjans JC, Bartsch H, Van Schooten FJ
- Issue date: 2001 Jul